183 related articles for article (PubMed ID: 11880793)
1. Construct validity of medicare chemotherapy claims: the case of 5FU.
Lamont EB; Lauderdale DS; Schilsky RL; Christakis NA
Med Care; 2002 Mar; 40(3):201-11. PubMed ID: 11880793
[TBL] [Abstract][Full Text] [Related]
2. Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment.
Cooper GS; Yuan Z; Stange KC; Dennis LK; Amini SB; Rimm AA
Med Care; 2000 Apr; 38(4):411-21. PubMed ID: 10752973
[TBL] [Abstract][Full Text] [Related]
3. Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage.
Chawla N; Yabroff KR; Mariotto A; McNeel TS; Schrag D; Warren JL
Ann Epidemiol; 2014 Sep; 24(9):666-72, 672.e1-2. PubMed ID: 25066409
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer.
Iwashyna TJ; Lamont EB
J Clin Oncol; 2002 Oct; 20(19):3992-8. PubMed ID: 12351596
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Medicare Claims-based Proxy Measures of Poor Function and Associations With Treatment Receipt and Mortality in Older Colon Cancer Patients.
Mayer SE; Tan HJ; Peacock Hinton S; Sanoff HK; Stürmer T; Hester LL; Faurot KR; Jonsson Funk M; Lund JL
Med Care; 2019 Apr; 57(4):286-294. PubMed ID: 30789540
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of three algorithms to identify incident breast cancer in Medicare claims data.
Gold HT; Do HT
Health Serv Res; 2007 Oct; 42(5):2056-69. PubMed ID: 17850533
[TBL] [Abstract][Full Text] [Related]
7. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer.
Sundararajan V; Mitra N; Jacobson JS; Grann VR; Heitjan DF; Neugut AI
Ann Intern Med; 2002 Mar; 136(5):349-57. PubMed ID: 11874307
[TBL] [Abstract][Full Text] [Related]
8. Identifying specific chemotherapeutic agents in Medicare data: a validation study.
Lund JL; Stürmer T; Harlan LC; Sanoff HK; Sandler RS; Brookhart MA; Warren JL
Med Care; 2013 May; 51(5):e27-34. PubMed ID: 22080337
[TBL] [Abstract][Full Text] [Related]
9. An algorithm for the use of Medicare claims data to identify women with incident breast cancer.
Nattinger AB; Laud PW; Bajorunaite R; Sparapani RA; Freeman JL
Health Serv Res; 2004 Dec; 39(6 Pt 1):1733-49. PubMed ID: 15533184
[TBL] [Abstract][Full Text] [Related]
10. Use of Bevacizumab for Elderly Patients With Stage IV Colon Cancer: Analysis of SEER-Medicare Data.
Raab GT; Lin A; Hillyer GC; Keller D; O'Neil DS; Accordino MK; Buono DL; Hur C; Kiran RP; Wright JD; Hershman DL; Neugut AI
Clin Colorectal Cancer; 2019 Sep; 18(3):e294-e299. PubMed ID: 31266707
[TBL] [Abstract][Full Text] [Related]
11. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data.
Du X; Goodwin JS
J Clin Oncol; 2001 Mar; 19(5):1455-61. PubMed ID: 11230491
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of administrative claims to identify incident cases of lung cancer: a comparison of 3 health plans.
Ramsey SD; Scoggins JF; Blough DK; McDermott CL; Reyes CM
J Manag Care Pharm; 2009 Oct; 15(8):659-68. PubMed ID: 19803555
[TBL] [Abstract][Full Text] [Related]
13. Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802).
Lamont EB; Yu M; He Y; Saltz L; Muss H; Zaslavsky AM;
J Geriatr Oncol; 2014 Jul; 5(3):230-7. PubMed ID: 24594119
[TBL] [Abstract][Full Text] [Related]
14. Completion of therapy by Medicare patients with stage III colon cancer.
Dobie SA; Baldwin LM; Dominitz JA; Matthews B; Billingsley K; Barlow W
J Natl Cancer Inst; 2006 May; 98(9):610-9. PubMed ID: 16670386
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of Medicare claims data for measuring use of standard multiagent chemotherapy regimens.
Lamont EB; Lan L
Med Care; 2014 Mar; 52(3):e15-20. PubMed ID: 22410411
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer.
Schrag D; Rifas-Shiman S; Saltz L; Bach PB; Begg CB
J Clin Oncol; 2002 Oct; 20(19):3999-4005. PubMed ID: 12351597
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Comorbid Medical Conditions in the National Cancer Database and the SEER-Medicare Database.
Lin CC; Virgo KS; Robbins AS; Jemal A; Ward EM
Ann Surg Oncol; 2016 Dec; 23(13):4139-4148. PubMed ID: 27535406
[TBL] [Abstract][Full Text] [Related]
18. Identifying Cancer-Directed Surgeries in Medicare Claims: A Validation Study Using SEER-Medicare Data.
Lavery JA; Lipitz-Snyderman A; Li DG; Bach PB; Panageas KS
JCO Clin Cancer Inform; 2019 Feb; 3():1-24. PubMed ID: 30715928
[TBL] [Abstract][Full Text] [Related]
19. Utility of the SEER-Medicare data to identify chemotherapy use.
Warren JL; Harlan LC; Fahey A; Virnig BA; Freeman JL; Klabunde CN; Cooper GS; Knopf KB
Med Care; 2002 Aug; 40(8 Suppl):IV-55-61. PubMed ID: 12187169
[TBL] [Abstract][Full Text] [Related]
20. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.
Lamont EB; Herndon JE; Weeks JC; Henderson IC; Lilenbaum R; Schilsky RL; Christakis NA
J Natl Cancer Inst; 2005 Jul; 97(14):1080-3. PubMed ID: 16030306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
